{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:20:36Z","timestamp":1792182036546,"version":"4.4.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09870-2","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:54:35Z","timestamp":1724345675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Antimicrobial resistance: use of phage therapy in the management of resistant infections"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9049-3316","authenticated-orcid":false,"given":"Favour","family":"Ikpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-655X","authenticated-orcid":false,"given":"Tonfamoworio","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-1927","authenticated-orcid":false,"given":"Edidiong","family":"Orok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Ikpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"7","key":"9870_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","volume":"109","author":"F Prestinaci","year":"2015","unstructured":"Prestinaci F, Pezzotti P, Pantosti A (2015) Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 109(7):309\u2013318. https:\/\/doi.org\/10.1179\/2047773215Y.0000000030","journal-title":"Pathog Glob Health"},{"key":"9870_CR2","unstructured":"O\u2019Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. review on antimicrobial resistance. Wellcome Trust and HM Government. https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf Accessed 12 April 2023"},{"key":"9870_CR3","unstructured":"World Health Organization. Antimicrobial resistance (2021) https:\/\/www.who.int\/newsroom\/fact-sheets\/detail\/antimicrobial-resistance. Accessed 23 April 2023"},{"key":"9870_CR4","unstructured":"Centers for Disease Control and Prevention: Antibiotic Resistance Threats in the United States (2019) https:\/\/www.cdc.gov\/drugresistance\/pdf\/threatsreport\/2019-ar-threats-report-508.pdf. Accessed 23 April, 2023"},{"key":"9870_CR5","unstructured":"World Health Organization. Global action plan on antimicrobial resistance (2015) https:\/\/apps.who.int\/iris\/handle\/10665\/193736. Accessed 23 May, 2023"},{"key":"9870_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nrmicro.2017.28","volume":"15","author":"TS Crofts","year":"2017","unstructured":"Crofts TS, Gasparrini AJ, Dantas G (2017) Next-generation approaches to understand and combat the antibiotic resistome. Nat Rev Microbiol 15:422\u2013434","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"9870_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chembiol.2015.05.017","volume":"22","author":"KJ Forsberg","year":"2015","unstructured":"Forsberg KJ, Patel S, Wencewicz TA, Dantas G (2015) The tetracycline destructases: a novel family of tetracycline-inactivating enzymes. Chem Biol 22(7):888\u2013897","journal-title":"Chem Biol"},{"key":"9870_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/cc8892","volume":"14","author":"K Bush","year":"2010","unstructured":"Bush K (2010) Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 14:224","journal-title":"Crit Care"},{"issue":"2","key":"9870_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","volume":"19","author":"LJV Piddock","year":"2006","unstructured":"Piddock LJV (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19(2):382\u2013402","journal-title":"Clin Microbiol Rev"},{"key":"9870_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias CA, Murray BE (2012) The rise of the Enterococcus: Beyond Vancomycin resistance. Nat Rev Microbiol 10:266\u2013278","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"9870_CR11","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1128\/AAC.02835-15","volume":"60","author":"B Babouee Flury","year":"2016","unstructured":"Babouee Flury B, Ellington MJ, Hopkins KL, Turton JF, Doumith M, Loy R, Staves P, Hinic V, Frei R, Woodford N (2016) Association of novel nonsynonymous single nucleotide polymorphisms in AmpD with cephalosporin resistance and phylogenetic variations in AmpC, AmpR, OmpF, and OmpC in Enterobacter cloacae isolates that are highly resistant to carbapenems. Antimicrob Agents Chemother 60(4):2383\u20132390","journal-title":"Antimicrob Agents Chemother"},{"key":"9870_CR12","doi-asserted-by":"crossref","unstructured":"Irfan M, Almotiri A, AlZeyadi ZA (2022) Antimicrobial resistance and its drivers\u2014A review.Antibiotics, 11(10), 1362","DOI":"10.3390\/antibiotics11101362"},{"issue":"2","key":"9870_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jiph.2021.12.008","volume":"15","author":"A Sharma","year":"2022","unstructured":"Sharma A, Singh A, Dar MA, Kaur RJ, Charan J, Iskandar K, Haque M, Murti K, Ravichandiran V, Dhingra S (2022) Menace of antimicrobial resistance in LMICs: current surveillance practices and control measures to tackle hostility. J Infect Public Health 15(2):172\u2013181. https:\/\/doi.org\/10.1016\/j.jiph.2021.12.008","journal-title":"J Infect Public Health"},{"key":"9870_CR14","doi-asserted-by":"publisher","unstructured":"Alhomoud F, Almahasnah R, Alhomoud FK (2018) You could lose when you misuse \u2013 factors affecting over-the-counter sale of antibiotics in community pharmacies in Saudi Arabia: a qualitative study. BMC Health Serv Res 18. https:\/\/doi.org\/10.1186\/s12913-018-3753-y","DOI":"10.1186\/s12913-018-3753-y"},{"issue":"8","key":"9870_CR15","first-page":"327","volume":"7","author":"P Khanal","year":"2020","unstructured":"Khanal P (2020) Antibiotic resistance: causes and consequences. Eur J Biomed Pharm Sci 7(8):327\u2013331","journal-title":"Eur J Biomed Pharm Sci"},{"key":"9870_CR16","unstructured":"Organisation for Economic Co-operation and Development. European Centre for Disease Prevention and Control. Antimicrobial resistance: tackling the burden in the European Union. Briefing note for EU\/EEA countries. Paris: OECD Publications (2019) https:\/\/www.oecd.org\/health\/health-systems\/AMR-Tackling-the-Burden-in-the-EU-OECD-ECDC-Briefing-Note-2019.pdf. Accessed 27 May, 2023"},{"issue":"51","key":"9870_CR17","doi-asserted-by":"publisher","first-page":"12896","DOI":"10.1073\/pnas.1721095115","volume":"115","author":"KP Klugman","year":"2018","unstructured":"Klugman KP, Black S (2018) Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci U S A 115(51):12896\u201312901. https:\/\/doi.org\/10.1073\/pnas.1721095115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"9870_CR18","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1080\/21645515.2018.1476814","volume":"14","author":"KU Jansen","year":"2018","unstructured":"Jansen KU, Anderson AS (2018) The role of vaccines in fighting antimicrobial resistance (AMR). Hum Vaccin Immunother 14(9):2142\u20132149. https:\/\/doi.org\/10.1080\/21645515.2018.1476814","journal-title":"Hum Vaccin Immunother"},{"issue":"19","key":"9870_CR19","doi-asserted-by":"publisher","first-page":"fnw210","DOI":"10.1093\/femsle\/fnw210","volume":"363","author":"BH Ter Kuile","year":"2016","unstructured":"Ter Kuile BH, Kraupner N, Brul S (2016) The risk of low concentrations of antibiotics in agriculture for resistance in human health care. FEMS Microbiol Lett 363(19):fnw210. https:\/\/doi.org\/10.1093\/femsle\/fnw210","journal-title":"FEMS Microbiol Lett"},{"key":"9870_CR20","doi-asserted-by":"publisher","unstructured":"Tang KL, Caffrey NP, N\u00f3brega DB, Cork SC, Ronksley PE, Barkema HW et al (2017) Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysis. Lancet Planet Health. ;1(8):e316-e327. https:\/\/doi.org\/10.1016\/S2542-5196(17)30141-9. Erratum in: Lancet Planet Health. 2017;1(9):e359","DOI":"10.1016\/S2542-5196(17)30141-9"},{"key":"9870_CR21","doi-asserted-by":"publisher","unstructured":"Van Boeckel TP, Pires J, Silvester R, Zhao C, Song J, Criscuolo NG, Gilbert M, Bonhoeffer S, Laxminarayan R (2019) Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science. ;365(6459):eaaw1944. https:\/\/doi.org\/10.1126\/science.aaw1944","DOI":"10.1126\/science.aaw"},{"issue":"10014","key":"9870_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","volume":"387","author":"AH Holmes","year":"2016","unstructured":"Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ (2016) Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387(10014):176\u2013187. https:\/\/doi.org\/10.1016\/S0140-6736(15)00473-0","journal-title":"Lancet"},{"issue":"3","key":"9870_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijfoodmicro.2011.05.025","volume":"152","author":"EF O\u2019Shea","year":"2012","unstructured":"O\u2019Shea EF, Cotter PD, Stanton C, Ross RP, Hill C (2012) Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol 152(3):189\u2013205. 10.1016\/j. ijfoodmicro.2011.05.025","journal-title":"Int J Food Microbiol"},{"key":"9870_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-12-814319-3.00006-4","volume":"18","author":"L Furci","year":"2018","unstructured":"Furci L, Secchi M (2018) AMPs and mechanisms of Antimicrobial Action. Antimicrob Peptides Gastrointest Dis 18:97\u2013131. https:\/\/doi.org\/10.1016\/B978-0-12-814319-3.00006-4","journal-title":"Antimicrob Peptides Gastrointest Dis"},{"issue":"6","key":"9870_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/v13061057","volume":"13","author":"JG McCutcheon","year":"2021","unstructured":"McCutcheon JG, Dennis JJ (2021) The potential of phage therapy against the Emerging Opportunistic Pathogen Stenotrophomonas maltophilia. Viruses 13(6):1057. https:\/\/doi.org\/10.3390\/v13061057","journal-title":"Viruses"},{"key":"9870_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1057\/s41599-020-0478-4","volume":"6","author":"C Brives","year":"2020","unstructured":"Brives C, Pourraz J (2020) Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun 6:100. https:\/\/doi.org\/10.1057\/s41599-020-0478-4","journal-title":"Palgrave Commun"},{"issue":"9","key":"9870_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1586\/eri.11.90","volume":"9","author":"B Burrowes","year":"2011","unstructured":"Burrowes B, Harper DR, Anderson J, McConville M, Enright MC (2011) Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 9(9):775\u2013785. https:\/\/doi.org\/10.1586\/eri.11.90","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"9870_CR28","doi-asserted-by":"publisher","first-page":"e0168615","DOI":"10.1371\/journal.pone.0168615","volume":"12","author":"WN Chaudhry","year":"2017","unstructured":"Chaudhry WN, Concepci\u00f3n-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR (2017) Synergy and Order effects of antibiotics and phages in Killing Pseudomonas aeruginosa Biofilms. PLoS ONE 12(1):e0168615. https:\/\/doi.org\/10.1371\/journal.pone.0168615","journal-title":"PLoS ONE"},{"issue":"1","key":"9870_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4236\/aim.2013.31008","volume":"3","author":"NH Narasimhaiah","year":"2013","unstructured":"Narasimhaiah NH (2013) Therapeutic potential of staphylococcal bacteriophages for nasal decolonization of Staphylococcus aureus in mice. Adv Microbiol 3(1):52\u201360","journal-title":"Adv Microbiol"},{"issue":"2","key":"9870_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/bact.1.2.14590","volume":"1","author":"C Loc-Carrillo","year":"2011","unstructured":"Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1(2):111\u2013114. https:\/\/doi.org\/10.4161\/bact.1.2.14590","journal-title":"Bacteriophage"},{"issue":"2","key":"9870_CR31","doi-asserted-by":"publisher","first-page":"e00211","DOI":"10.1128\/mBio.00211-21","volume":"12","author":"KC Salazar","year":"2021","unstructured":"Salazar KC, Ma L, Green SI, Zulk JJ, Trautner BW, Ramig RF, Clark JR, Terwilliger AL, Maresso AW (2021) Antiviral resistance and phage counter adaptation to antibiotic-resistant Extraintestinal Pathogenic Escherichia coli. mBio 12(2):e00211\u2013e00221. https:\/\/doi.org\/10.1128\/mBio.00211-21","journal-title":"mBio"},{"issue":"4","key":"9870_CR32","doi-asserted-by":"publisher","first-page":"e0034522","DOI":"10.1128\/msphere.00345-22","volume":"7","author":"JJ Zulk","year":"2022","unstructured":"Zulk JJ, Clark JR, Ottinger S, Ballard MB, Mejia ME, Mercado-Evans V, Heckmann ER, Sanchez BC, Trautner BW, Maresso AW, Patras KA (2022) Phage resistance accompanies reduced fitness of Uropathogenic Escherichia coli in the urinary environment. mSphere 7(4):e0034522. https:\/\/doi.org\/10.1128\/msphere.00345-22","journal-title":"mSphere"},{"issue":"1","key":"9870_CR33","doi-asserted-by":"publisher","first-page":"fuab048","DOI":"10.1093\/femsre\/fuab048","volume":"46","author":"JE Egido","year":"2022","unstructured":"Egido JE, Costa AR, Aparicio-Maldonado C, Haas PJ, Brouns SJJ (2022) Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol Rev 46(1):fuab048. https:\/\/doi.org\/10.1093\/femsre\/fuab048","journal-title":"FEMS Microbiol Rev"},{"issue":"12","key":"9870_CR34","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3390\/molecules22122174","volume":"22","author":"K Witek","year":"2017","unstructured":"Witek K, Nasim MJ, Bischoff M, Gaupp R, Arsenyan P, Vasiljeva J et al (2017) Selenazolinium salts as small molecule catalysts with high potency against ESKAPE bacterial pathogens. Molecules 22(12):2174. https:\/\/doi.org\/10.3390\/molecules22122174","journal-title":"Molecules"},{"key":"9870_CR35","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3389\/fmicb.2018.02154","volume":"9","author":"D Sun","year":"2018","unstructured":"Sun D (2018) Pull in and push out: mechanism of horizontal gene transfer in bacteria. Front Microbiol 9:2154. https:\/\/doi.org\/10.3389\/fmicb.2018.02154","journal-title":"Front Microbiol"},{"key":"9870_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.fct.2008.02.006","volume":"47","author":"BG Kelly","year":"2009","unstructured":"Kelly BG, Vespermann A, Bolton DJ (2009) The role of horizontal gene transfer in the evolution of selected foodbiome bacterial pathogen. Food Chem Toxicol 47:951\u2013968","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"9870_CR37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cell.2007.03.004","volume":"128","author":"MN Alekshun","year":"2007","unstructured":"Alekshun MN, Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell 128(6):1037\u20131050. https:\/\/doi.org\/10.1016\/j.cell.2007.03.004","journal-title":"Cell"},{"key":"9870_CR38","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMra1813799","volume":"380","author":"RC Boucher","year":"2019","unstructured":"Boucher RC (2019) Muco-Obstructive Lung diseases. New Engl J Med 380:1941\u20131953","journal-title":"New Engl J Med"},{"key":"9870_CR39","doi-asserted-by":"publisher","unstructured":"Cao F, Wang X, Wang L, Li Z, Che J, Wang L et al (2015) Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int. ; 2015:752930. https:\/\/doi.org\/10.1155\/2015\/752930","DOI":"10.1155\/2015\/752930"},{"issue":"1","key":"9870_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4102\/ajlm.v5i1.435","volume":"5","author":"JMO Oduor","year":"2016","unstructured":"Oduor JMO, Onkoba N, Maloba F, Nyachieo A (2016) Experimental phage therapy against haematogenous multi-drug resistant Staphylococcus aureus pneumonia in mice. Afr J Lab Med 5(1):435. https:\/\/doi.org\/10.4102\/ajlm.v5i1.435","journal-title":"Afr J Lab Med"},{"issue":"4","key":"9870_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","volume":"47","author":"N Law","year":"2019","unstructured":"Law N, Logan C, Yung G, Furr CL, Lehman SM, Morales S et al (2019) Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 47(4):665\u2013668. https:\/\/doi.org\/10.1007\/s15010-019-01319-0","journal-title":"Infection"},{"issue":"11","key":"9870_CR42","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/ppul.24945","volume":"55","author":"AB Gainey","year":"2020","unstructured":"Gainey AB, Burch AK, Brownstein MJ, Brown DE, Fackler J, Horne B et al (2020) Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol 55(11):2990\u20132994. https:\/\/doi.org\/10.1002\/ppul.24945","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"9870_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.medmal.2008.06.023","volume":"38","author":"M Kutateladze","year":"2008","unstructured":"Kutateladze M, Adamia R (2008) Phage therapy experience at the Eliava Institute. Med Mal Infect 38(8):426\u2013430. https:\/\/doi.org\/10.1016\/j.medmal.2008.06.023","journal-title":"Med Mal Infect"},{"issue":"9","key":"9870_CR44","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3201\/eid1009.040069","volume":"10","author":"EW Tiemersma","year":"2004","unstructured":"Tiemersma EW, Bronzwaer SL, Lyytik\u00e4inen O, Degener JE, Schrijnemakers P, Bruinsma N et al (2004) Methicillin-resistant Staphylococcus aureus in Europe, 1999\u20132002. Emerg Infect Dis 10(9):1627\u20131634. https:\/\/doi.org\/10.3201\/eid1009.040069","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"9870_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2019.296","volume":"41","author":"LM Weiner-Lastinger","year":"2020","unstructured":"Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS et al (2020) Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015\u20132017. Infect Control Hosp Epidemiol 41(1):1\u201318. https:\/\/doi.org\/10.1017\/ice.2019.296","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"9870_CR46","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1472-765X.2012.03205.x","volume":"54","author":"D Kelly","year":"2012","unstructured":"Kelly D, McAuliffe O, Ross RP, Coffey A (2012) Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives. Lett Appl Microbiol 54(4):286\u2013291. https:\/\/doi.org\/10.1111\/j.1472-765X.2012.03205.x","journal-title":"Lett Appl Microbiol"},{"issue":"4","key":"9870_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/138920108785161604","volume":"9","author":"J Azeredo","year":"2008","unstructured":"Azeredo J, Sutherland IW (2008) The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9(4):261\u2013266. https:\/\/doi.org\/10.2174\/138920108785161604","journal-title":"Curr Pharm Biotechnol"},{"key":"9870_CR48","unstructured":"de Vries J An overview: Staphylococcus aureus Phage Therapy. Groningen: University of Groningen.2019. https:\/\/fse.studenttheses.ub.rug.nl\/20647\/ Accessed 23 June, 2023"},{"issue":"6","key":"9870_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1473-3099(20)30200-0","volume":"20","author":"FX Lescure","year":"2020","unstructured":"Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S et al (2020) Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 20(6):697\u2013706. https:\/\/doi.org\/10.1016\/S1473-3099(20)30200-0","journal-title":"Lancet Infect Dis"},{"key":"9870_CR50","doi-asserted-by":"publisher","unstructured":"Alrahmany D, Omar AF, Harb G, El Nekidy WS, Ghazi IM (2021) 25;10(6):630 Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes. Antibiotics (Basel). https:\/\/doi.org\/10.3390\/antibiotics10060630","DOI":"10.3390\/antibiotics10060630"},{"key":"9870_CR51","doi-asserted-by":"publisher","first-page":"100113","DOI":"10.1016\/j.infpip.2021.100113","volume":"3","author":"T Gottesman","year":"2021","unstructured":"Gottesman T, Fedorowsky R, Yerushalmi R, Lellouche J, Nutman A (2021) An outbreak of carbapenem-resistant Acinetobacter baumannii in a COVID-19 dedicated hospital. Infect Prev Pract 3:100113","journal-title":"Infect Prev Pract"},{"key":"9870_CR52","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3389\/fmicb.2017.02659","volume":"8","author":"Y Hua","year":"2018","unstructured":"Hua Y, Luo T, Yang Y, Dong D, Wang R, Wang Y et al (2018) Phage therapy as a Promising New treatment for lung infection caused by Carbapenem-Resistant Acinetobacter baumannii in mice. Front Microbiol 8:2659. https:\/\/doi.org\/10.3389\/fmicb.2017.02659","journal-title":"Front Microbiol"},{"issue":"10","key":"9870_CR53","doi-asserted-by":"publisher","first-page":"e00954","DOI":"10.1128\/AAC.00954-17","volume":"61","author":"RT Schooley","year":"2017","unstructured":"Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L et al (2017) Development and Use of Personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61(10):e00954\u2013e00917. https:\/\/doi.org\/10.1128\/AAC.00954-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"9870_CR54","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/cid\/ciz222","volume":"69","author":"R Nir-Paz","year":"2019","unstructured":"Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S et al (2019) Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis 69(11):2015\u20132018. https:\/\/doi.org\/10.1093\/cid\/ciz222","journal-title":"Clin Infect Dis"},{"key":"9870_CR55","doi-asserted-by":"publisher","first-page":"631585","DOI":"10.3389\/fcimb.2021.631585","volume":"11","author":"X Tan","year":"2021","unstructured":"Tan X, Chen H, Zhang M, Zhao Y, Jiang Y, Liu X et al (2021) Clinical experience of personalized phage therapy against carbapenem-resistant acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Front Cell Infect Microbiol 11:631585. https:\/\/doi.org\/10.3389\/fcimb.2021.631585","journal-title":"Front Cell Infect Microbiol"},{"key":"9870_CR56","doi-asserted-by":"publisher","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","volume":"5","author":"S LaVergne","year":"2018","unstructured":"LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley RT, Wooten D (2018) Phage therapy for a multidrug-resistant Acineto bacter baumannii craniectomy site infection. Open Forum Infect Dis 5:ofy064","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"9870_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.virol.2009.03.009","volume":"388","author":"E Denou","year":"2009","unstructured":"Denou E, Bruttin A, Barretto C, Ngom-Bru C, Br\u00fcssow H, Zuber S (2009) T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388(1):21\u201330. https:\/\/doi.org\/10.1016\/j.virol.2009.03.009","journal-title":"Virology"},{"issue":"3","key":"9870_CR58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"DM Lin","year":"2017","unstructured":"Lin DM, Koskella B, Lin HC (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8(3):162\u2013173. https:\/\/doi.org\/10.4292\/wjgpt.v8.i3.162","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"9870_CR59","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","volume":"49","author":"A Bruttin","year":"2005","unstructured":"Bruttin A, Br\u00fcssow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874\u20132878","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"9870_CR60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/v10070351","volume":"10","author":"F Oechslin","year":"2018","unstructured":"Oechslin F (2018) Resistance Development to bacteriophages occurring during bacteriophage therapy. Viruses 10(7):351. https:\/\/doi.org\/10.3390\/v10070351","journal-title":"Viruses"},{"issue":"16","key":"9870_CR61","doi-asserted-by":"publisher","first-page":"fny136","DOI":"10.1093\/femsle\/fny136","volume":"365","author":"A Vahedi","year":"2018","unstructured":"Vahedi A, Soltan Dallal MM, Douraghi M, Nikkhahi F, Rajabi Z, Yousefi M et al (2018) Isolation and identification of specific bacteriophage against enteropathogenic Escherichia coli (EPEC) and in vitro and in vivo characterization of bacteriophage. FEMS Microbiol Lett 365(16):fny136. https:\/\/doi.org\/10.1093\/femsle\/fny136","journal-title":"FEMS Microbiol Lett"},{"issue":"7","key":"9870_CR62","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/1462-2920.13284","volume":"18","author":"M Galtier","year":"2016","unstructured":"Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA et al (2016) Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol 18(7):2237\u20132245. https:\/\/doi.org\/10.1111\/1462-2920.13284","journal-title":"Environ Microbiol"},{"key":"9870_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","volume":"70","author":"P Hyman","year":"2010","unstructured":"Hyman P, Abedon ST (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217\u2013248. https:\/\/doi.org\/10.1016\/S0065-2164(10)70007-1","journal-title":"Adv Appl Microbiol"},{"key":"9870_CR64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00284-010-9699-x","volume":"62","author":"R Gupta","year":"2011","unstructured":"Gupta R, Prasad Y (2011) Efficacy of polyvalent bacteriophage p-27\/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr Microbiol 62:255\u2013260. https:\/\/doi.org\/10.1007\/s00284-010-9699-x","journal-title":"Curr Microbiol"},{"key":"9870_CR65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/genetics\/28.6.491","volume":"28","author":"SE Luria","year":"1943","unstructured":"Luria SE, Delbruck M (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491\u2013511","journal-title":"Genetics"},{"key":"9870_CR66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2315","volume":"8","author":"SJ Labrie","year":"2010","unstructured":"Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317\u2013327. https:\/\/doi.org\/10.1038\/nrmicro2315","journal-title":"Nat Rev Microbiol"},{"key":"9870_CR67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1086\/648478","volume":"201","author":"R Capparelli","year":"2010","unstructured":"Capparelli R, Nocerino N, Iannaccone M, Ercolini D, Parlato M, Chiara M et al (2010) Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy. J Infect Dis 201:52\u201361. https:\/\/doi.org\/10.1086\/648478","journal-title":"J Infect Dis"},{"issue":"1","key":"9870_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/bact.1.1.13980","volume":"1","author":"ST Abedon","year":"2011","unstructured":"Abedon ST (2011) Lysis from without. Bacteriophage 1(1):46\u201349. https:\/\/doi.org\/10.4161\/bact.1.1.13980","journal-title":"Bacteriophage"},{"issue":"1","key":"9870_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/138920110790725410","volume":"11","author":"ST Abedon","year":"2010","unstructured":"Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11(1):28\u201347. https:\/\/doi.org\/10.2174\/138920110790725410","journal-title":"Curr Pharm Biotechnol"},{"key":"9870_CR70","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.tibtech.2010.08.001","volume":"28","author":"M Kutateladze","year":"2010","unstructured":"Kutateladze M, Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591\u2013595","journal-title":"Trends Biotechnol"},{"key":"9870_CR71","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10529-007-9346-1","volume":"29","author":"M Skurnik","year":"2007","unstructured":"Skurnik M, Pajunen M, Kiljunen S (2007) Biotechnological challenges of phage therapy. Biotechnol Lett 29:995\u20131003. https:\/\/doi.org\/10.1007\/s10529-007-9346-1","journal-title":"Biotechnol Lett"},{"key":"9870_CR72","doi-asserted-by":"publisher","unstructured":"Xu HM, Xu WM, Zhang L Current status of phage therapy against Infectious diseases and potential application beyond Infectious diseases. Int J Clin Pract. 2022:4913146. https:\/\/doi.org\/10.1155\/2022\/4913146","DOI":"10.1155\/2022\/4913146"},{"issue":"2","key":"9870_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41385-019-0250-5","volume":"13","author":"R Sausset","year":"2020","unstructured":"Sausset R, Petit MA, Gaboriau-Routhiau V, De Paepe M (2020) New insights into intestinal phages. Mucosal Immunol 13(2):205\u2013215. https:\/\/doi.org\/10.1038\/s41385-019-0250-5","journal-title":"Mucosal Immunol"},{"key":"9870_CR74","doi-asserted-by":"publisher","first-page":"1083208","DOI":"10.3389\/fmicb.2022.1083208","volume":"13","author":"D Rothschild-Rodriguez","year":"2023","unstructured":"Rothschild-Rodriguez D, Hedges M, Kaplan M, Karav S, Nobrega FL (2023) Phage-encoded carbohydrate-interacting proteins in the human gut. Front Microbiol 13:1083208. https:\/\/doi.org\/10.3389\/fmicb.2022.1083208","journal-title":"Front Microbiol"},{"issue":"5","key":"9870_CR75","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/microorganisms11051181","volume":"11","author":"L Chen","year":"2023","unstructured":"Chen L, Hou X, Chu H (2023) The Novel role of phage particles in Chronic Liver diseases. Microorganisms 11(5):1181. https:\/\/doi.org\/10.3390\/microorganisms11051181","journal-title":"Microorganisms"},{"key":"9870_CR76","doi-asserted-by":"publisher","first-page":"1097124","DOI":"10.3389\/frmbi.2022.1097124","volume":"1","author":"AD Tadmor","year":"2023","unstructured":"Tadmor AD, Mahmoudabadi G, Foley HB, Phillips R (2023) Identification and spatio-temporal tracking of ubiquitous phage families in the human microbiome. Front Microbiomes 1:1097124. https:\/\/doi.org\/10.3389\/frmbi.2022.1097124","journal-title":"Front Microbiomes"},{"key":"9870_CR77","doi-asserted-by":"publisher","unstructured":"Tobin C, Hill, Shkoporov A (2023) Factors affecting variation of the human gut phageome. Annu Rev Microbiol 77. https:\/\/doi.org\/10.1146\/annurev-micro-032421-105754","DOI":"10.1146\/annurev-micro-032421-105754"},{"key":"9870_CR78","doi-asserted-by":"publisher","first-page":"1213625","DOI":"10.3389\/fmicb.2023.1213625","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang R (2023) The human gut phageome: composition, development, and alterations in disease. Front Microbiol 14:1213625. https:\/\/doi.org\/10.3389\/fmicb.2023.1213625","journal-title":"Front Microbiol"},{"issue":"22","key":"9870_CR79","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.1128\/AEM.06331-11","volume":"77","author":"MS Kim","year":"2011","unstructured":"Kim MS, Park EJ, Roh SW, Bae JW (2011) Diversity and abundance of single-stranded DNA viruses in human feces. Appl Environ Microbiol 77(22):8062\u20138070. https:\/\/doi.org\/10.1128\/AEM.06331-11","journal-title":"Appl Environ Microbiol"},{"issue":"10","key":"9870_CR80","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.resmic.2014.10.006","volume":"165","author":"L Hoyles","year":"2014","unstructured":"Hoyles L, McCartney AL, Neve H, Gibson GR, Sanderson JD, Heller KJ et al (2014) Characterization of virus-like particles associated with the human faecal and caecal microbiota. Res Microbiol 165(10):803\u2013812. https:\/\/doi.org\/10.1016\/j.resmic.2014.10.006","journal-title":"Res Microbiol"},{"issue":"4","key":"9870_CR81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.chom.2019.09.009","volume":"26","author":"AN Shkoporov","year":"2019","unstructured":"Shkoporov AN, Clooney AG, Sutton TDS, Ryan FJ, Daly KM, Nolan JA et al (2019) The human gut virome is highly diverse, stable, and individual specific. Cell Host Microbe 26(4):527\u2013541e5. https:\/\/doi.org\/10.1016\/j.chom.2019.09.009","journal-title":"Cell Host Microbe"},{"key":"9870_CR82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40779-017-0122-9","volume":"4","author":"N Shi","year":"2017","unstructured":"Shi N, Li N, Duan X, Niu H (2017) Interaction between the gut microbiome and mucosal immune system. Mil Med Res 4:14. https:\/\/doi.org\/10.1186\/s40779-017-0122-9","journal-title":"Mil Med Res"},{"issue":"2","key":"9870_CR83","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.chom.2019.01.018","volume":"25","author":"L De Sordi","year":"2019","unstructured":"De Sordi L, Louren\u00e7o M, Debarbieux L (2019) The battle within: interactions of bacteriophages and Bacteria in the gastrointestinal tract. Cell Host Microbe 25(2):210\u2013218. https:\/\/doi.org\/10.1016\/j.chom.2019.01.018","journal-title":"Cell Host Microbe"},{"issue":"7","key":"9870_CR84","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrmicro.2017.30","volume":"15","author":"MK Mirzaei","year":"2017","unstructured":"Mirzaei MK, Maurice CF (2017) M\u00e9nage \u00e0 Trois in the human gut: interactions between host, bacteria and phages. Nat Rev Microbiol 15(7):397\u2013408. https:\/\/doi.org\/10.1038\/nrmicro.2017.30","journal-title":"Nat Rev Microbiol"},{"issue":"7790","key":"9870_CR85","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-019-1894-8","volume":"577","author":"HG Hampton","year":"2020","unstructured":"Hampton HG, Watson BNJ, Fineran PC (2020) The arms race between bacteria and their phage foes. Nature 577(7790):327\u2013336. https:\/\/doi.org\/10.1038\/s41586-019-1894-8","journal-title":"Nature"},{"issue":"10","key":"9870_CR86","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrmicro3527","volume":"13","author":"R Feiner","year":"2015","unstructured":"Feiner R, Argov T, Rabinovich L, Sigal N, Borovok I, Herskovits AA (2015) A new perspective on lysogeny: prophages as active regulatory switches of bacteria. Nat Rev Microbiol 13(10):641\u2013650. https:\/\/doi.org\/10.1038\/nrmicro3527","journal-title":"Nat Rev Microbiol"},{"key":"9870_CR87","doi-asserted-by":"crossref","unstructured":"Stuart Chapin FIII, Matson PA, Vitousek P (2011) Principles of terrestrial ecosystem ecology. New York, USA: Springer Science & Business Media. https:\/\/educons.edu.rs\/wp-content\/uploads\/2020\/05\/2011-Principles-Of-Terrestrial-Ecosystem-Ecology.pdf. Accessed 23 May, 2023","DOI":"10.1007\/978-1-4419-9504-9_2"},{"key":"9870_CR88","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/microorganisms6020054","volume":"6","author":"G Tetz","year":"2018","unstructured":"Tetz G, Tetz V (2018) Bacteriophages as New Human viral pathogens. Microorganisms 6:54. https:\/\/doi.org\/10.3390\/microorganisms6020054","journal-title":"Microorganisms"},{"key":"9870_CR89","doi-asserted-by":"publisher","first-page":"10812","DOI":"10.1038\/s41598-018-29173-4","volume":"8","author":"G Tetz","year":"2018","unstructured":"Tetz G, Brown SM, Hao Y, Tetz V (2018) Parkinson\u2019s disease and bacteriophages as its overlooked contributors. Sci Rep 8:10812. 10.1038\/ s41598-018-29173-4","journal-title":"Sci Rep"},{"key":"9870_CR90","doi-asserted-by":"publisher","first-page":"G171","DOI":"10.1152\/ajpgi.00048.2015","volume":"312","author":"JM Wells","year":"2017","unstructured":"Wells JM, Brummer RJ, Derrien M, MacDonald TT, Troost F, Cani PD et al (2017) Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol 312:G171\u2013G193. https:\/\/doi.org\/10.1152\/ajpgi.00048.2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"9870_CR91","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.mib.2014.11.019","volume":"23","author":"JR Penad\u00e9s","year":"2015","unstructured":"Penad\u00e9s JR, Chen J, Quiles-Puchalt N, Carpena N, Novick RP (2015) Bacteriophage-mediated spread of bacterial virulence genes. Curr Opin Microbiol 23:171\u2013178. https:\/\/doi.org\/10.1016\/j.mib.2014.11.019","journal-title":"Curr Opin Microbiol"},{"key":"9870_CR92","doi-asserted-by":"publisher","unstructured":"Lin DM, Lin HC A theoretical model of temperate phages as mediators of gut microbiome dysbiosis. F1000Res. 2019;8:F1000 Faculty Rev-997. https:\/\/doi.org\/10.12688\/f1000research.18480.1","DOI":"10.12688\/f1000research.18480.1"},{"issue":"4","key":"9870_CR93","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41423-020-00532-4","volume":"18","author":"S Federici","year":"2021","unstructured":"Federici S, Nobs SP, Elinav E (2021) Phages and their potential to modulate the microbiome and immunity. Cell Mol Immunol 18(4):889\u2013904. https:\/\/doi.org\/10.1038\/s41423-020-00532-4","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"9870_CR94","doi-asserted-by":"publisher","first-page":"536","DOI":"10.4142\/jvs.2018.19.4.536","volume":"19","author":"G Won","year":"2018","unstructured":"Won G, Eo SK, Park SY, Hur J, Lee JH (2018) A Salmonella Typhi ghost induced by the E gene of phage \u03c6X174 stimulates dendritic cells and efficiently activates the adaptive immune response. J Vet Sci 19(4):536\u2013542. https:\/\/doi.org\/10.4142\/jvs.2018.19.4.536","journal-title":"J Vet Sci"},{"issue":"17","key":"9870_CR95","doi-asserted-by":"publisher","first-page":"e98045","DOI":"10.15252\/embj.201798045","volume":"37","author":"H Yang","year":"2018","unstructured":"Yang H, Xu J, Li W, Wang S, Li J, Yu J et al (2018) Staphylococcus aureus virulence attenuation and immune clearance mediated by a phage lysin-derived protein. EMBO J 37(17):e98045. https:\/\/doi.org\/10.15252\/embj.201798045","journal-title":"EMBO J"},{"issue":"19","key":"9870_CR96","doi-asserted-by":"publisher","first-page":"7615","DOI":"10.1074\/jbc.RA118.006968","volume":"294","author":"Y Yang","year":"2019","unstructured":"Yang Y, Liu Z, He X, Yang J, Wu J, Yang H, Li M, Qian Q, Lai R, Xu W, Wei L (2019) A small mycobacteriophage-derived peptide and its improved isomer restrict mycobacterial infection via dual mycobactericidal-immunoregulatory activities. J Biol Chem 294(19):7615\u20137631. https:\/\/doi.org\/10.1074\/jbc.RA118.006968","journal-title":"J Biol Chem"},{"issue":"3","key":"9870_CR97","doi-asserted-by":"publisher","first-page":"937","DOI":"10.4049\/jimmunol.1701067","volume":"200","author":"M Tian","year":"2018","unstructured":"Tian M, Hua Z, Hong S, Zhang Z, Liu C, Lin L et al (2018) B cell-intrinsic MyD88 signaling promotes initial cell proliferation and differentiation to enhance the germinal center response to a virus-like particle. J Immunol 200(3):937\u2013948. https:\/\/doi.org\/10.4049\/jimmunol.1701067","journal-title":"J Immunol"},{"issue":"6434","key":"9870_CR98","doi-asserted-by":"publisher","first-page":"eaat9691","DOI":"10.1126\/science.aat9691","volume":"363","author":"JM Sweere","year":"2019","unstructured":"Sweere JM, Van Belleghem JD, Ishak H, Bach MS, Popescu M, Sunkari V et al (2019) Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 363(6434):eaat9691. https:\/\/doi.org\/10.1126\/science.aat9691","journal-title":"Science"},{"issue":"7","key":"9870_CR99","doi-asserted-by":"publisher","first-page":"973","DOI":"10.15252\/emmm.201404525","volume":"7","author":"R Sartorius","year":"2015","unstructured":"Sartorius R, D\u2019Apice L, Trovato M, Cuccaro F, Costa V, De Leo MG et al (2015) Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. EMBO Mol Med 7(7):973\u2013988. https:\/\/doi.org\/10.15252\/emmm.201404525","journal-title":"EMBO Mol Med"},{"issue":"1","key":"9870_CR100","doi-asserted-by":"publisher","first-page":"e10142","DOI":"10.1002\/btm2.10142","volume":"5","author":"KL Hess","year":"2019","unstructured":"Hess KL, Jewell CM (2019) Phage display as a tool for vaccine and immunotherapy development. Bioeng Translational Med 5(1):e10142. https:\/\/doi.org\/10.1002\/btm2.10142","journal-title":"Bioeng Translational Med"},{"issue":"4","key":"9870_CR101","doi-asserted-by":"publisher","first-page":"e0284708","DOI":"10.1371\/journal.pone.0284708","volume":"18","author":"T Chanpong","year":"2023","unstructured":"Chanpong T, Seesuay W, Chiangjong W, Jiramornimit P, Preedagasamzin S, Atjanasuppat K, Jittorntrum B, Prasongtanakij S, Tawinwung S, Pukiat S, Saisawang C, Borwornpinyo S, Chaichumpa W, Hongeng S, Anurathapan U (2023) A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: a potential targeted immunotherapy. PLoS ONE 18(4):e0284708. https:\/\/doi.org\/10.1371\/journal.pone.0284708","journal-title":"PLoS ONE"},{"issue":"5","key":"9870_CR102","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/vaccines11050919","volume":"11","author":"M Ragothaman","year":"2023","unstructured":"Ragothaman M, Yoo SY (2023) Engineered Phage-Based Cancer vaccines: current advances and future directions. Vaccines 11(5):919. https:\/\/doi.org\/10.3390\/vaccines11050919","journal-title":"Vaccines"},{"issue":"4","key":"9870_CR103","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/molecules25040843","volume":"25","author":"M Goracci","year":"2020","unstructured":"Goracci M, Pignochino Y, Marchi\u00f2 S (2020) Phage Display-based nanotechnology applications in Cancer Immunotherapy. Molecules 25(4):843. https:\/\/doi.org\/10.3390\/molecules25040843","journal-title":"Molecules"},{"issue":"2","key":"9870_CR104","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/pathogens12020314","volume":"12","author":"TG Soyer","year":"2023","unstructured":"Soyer TG, Ramos FF, Pereira IA, Lage DP, Bandeira RS, De Jesus MM, Costa GP, Machado AS, Freitas CS, Vale DL, Martins VT, Galdino AS, Duarte AM, Roatt MC, Coelho BM, E. A., Tavares GS (2023) Immunotherapy using Immunogenic Mimotopes selected by Phage Display plus Amphotericin B inducing a therapeutic response in mice infected with Leishmania amazonensis. Pathogens 12(2):314. https:\/\/doi.org\/10.3390\/pathogens12020314","journal-title":"Pathogens"},{"issue":"4","key":"9870_CR105","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12560-021-09483-z","volume":"13","author":"G Kaur","year":"2021","unstructured":"Kaur G, Agarwal R, Sharma RK (2021) Bacteriophage therapy for critical and high-priority antibiotic-resistant bacteria and phage cocktail-antibiotic formulation perspective. Food Environ Virol 13(4):433\u2013446. https:\/\/doi.org\/10.1007\/s12560-021-09483-z","journal-title":"Food Environ Virol"},{"issue":"5","key":"9870_CR106","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00253-019-09629-x","volume":"103","author":"AH Azam","year":"2019","unstructured":"Azam AH, Tanji Y (2019) Bacteriophage-host arm race: an update on the mechanism of phage resistance in bacteria and revenge of the phage with the perspective for phage therapy. Appl Microbiol Biotechnol 103(5):2121\u20132131. https:\/\/doi.org\/10.1007\/s00253-019-09629-x","journal-title":"Appl Microbiol Biotechnol"},{"issue":"7","key":"9870_CR107","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/v13071268","volume":"13","author":"D Liu","year":"2021","unstructured":"Liu D, Van Belleghem JD, de Vries CR, Burgener E, Chen Q, Manasherob R et al (2021) The safety and toxicity of phage therapy: a review of animal and clinical studies. Viruses 13(7):1268. https:\/\/doi.org\/10.3390\/v13071268","journal-title":"Viruses"},{"issue":"3","key":"9870_CR108","doi-asserted-by":"publisher","first-page":"e0207121","DOI":"10.1128\/AAC.02071-21","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S et al (2022) Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother 66(3):e0207121. https:\/\/doi.org\/10.1128\/AAC.02071-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"7304","key":"9870_CR109","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nature09199","volume":"466","author":"A Reyes","year":"2010","unstructured":"Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F et al (2010) Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466(7304):334\u2013338. https:\/\/doi.org\/10.1038\/nature09199","journal-title":"Nature"},{"issue":"11","key":"9870_CR110","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1038\/ismej.2016.47","volume":"10","author":"M Touchon","year":"2016","unstructured":"Touchon M, Bernheim A, Rocha EP (2016) Genetic and life-history traits associated with the distribution of prophages in bacteria. ISME J 10(11):2744\u20132754. https:\/\/doi.org\/10.1038\/ismej.2016.47","journal-title":"ISME J"},{"issue":"3","key":"9870_CR111","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41396-019-0566-x","volume":"14","author":"JK Cornuault","year":"2020","unstructured":"Cornuault JK, Moncaut E, Loux V, Mathieu A, Sokol H, Petit MA et al (2020) The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. ISME J 14(3):771\u2013787. https:\/\/doi.org\/10.1038\/s41396-019-0566-x","journal-title":"ISME J"},{"issue":"2","key":"9870_CR112","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/femsre\/fuv048","volume":"40","author":"RA Edwards","year":"2016","unstructured":"Edwards RA, McNair K, Faust K, Raes J, Dutilh BE (2016) Computational approaches to predict bacteriophage-host relationships. FEMS Microbiol Rev 40(2):258\u2013272. https:\/\/doi.org\/10.1093\/femsre\/fuv048","journal-title":"FEMS Microbiol Rev"},{"issue":"10","key":"9870_CR113","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1101\/gr.138297.112","volume":"22","author":"A Stern","year":"2012","unstructured":"Stern A, Mick E, Tirosh I, Sagy O, Sorek R (2012) CRISPR targeting reveals a reservoir of common phages associated with the human gut microbiome. Genome Res 22(10):1985\u20131994. https:\/\/doi.org\/10.1101\/gr.138297.112","journal-title":"Genome Res"},{"issue":"19","key":"9870_CR114","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1093\/bioinformatics\/btx383","volume":"33","author":"C Galiez","year":"2017","unstructured":"Galiez C, Siebert M, Enault F, Vincent J, S\u00f6ding J (2017) WIsH: who is the host? Predicting prokaryotic hosts from metagenomic phage contigs. Bioinformatics 33(19):3113\u20133114. https:\/\/doi.org\/10.1093\/bioinformatics\/btx383","journal-title":"Bioinformatics"},{"issue":"2","key":"9870_CR115","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.chom.2019.01.019","volume":"25","author":"JL Moreno-Gallego","year":"2019","unstructured":"Moreno-Gallego JL, Chou SP, Di Rienzi SC, Goodrich JK, Spector TD, Bell JT et al (2019) Virome Diversity Correlates with intestinal microbiome diversity in adult monozygotic twins. Cell Host Microbe 25(2):261\u2013272e5. https:\/\/doi.org\/10.1016\/j.chom.2019.01.019","journal-title":"Cell Host Microbe"},{"key":"9870_CR116","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4172\/1747-0862.1000050","volume":"6","author":"HM Parracho","year":"2012","unstructured":"Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR (2012) The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genetic Medicine: Int J Biomedical Res 6:279\u2013286. https:\/\/doi.org\/10.4172\/1747-0862.1000050","journal-title":"J Mol Genetic Medicine: Int J Biomedical Res"},{"issue":"5","key":"9870_CR117","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/med.21572","volume":"39","author":"K D\u0105browska","year":"2019","unstructured":"D\u0105browska K (2019) Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev 39(5):2000\u20132025. https:\/\/doi.org\/10.1002\/med.21572","journal-title":"Med Res Rev"},{"key":"9870_CR118","doi-asserted-by":"publisher","first-page":"418978","DOI":"10.3389\/fcimb.2018.00376","volume":"8","author":"LL Furfaro","year":"2018","unstructured":"Furfaro LL, Payne MS, Chang BJ (2018) Bacteriophage therapy: clinical trials and Regulatory hurdles. Front Cell Infect Microbiol 8:418978. https:\/\/doi.org\/10.3389\/fcimb.2018.00376","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"9870_CR119","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/ph16111615","volume":"16","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M (2023) Origin of antibiotics and antibiotic resistance, and their impacts on Drug Development: a narrative review. Pharmaceuticals (Basel Switzerland) 16(11):1615. https:\/\/doi.org\/10.3390\/ph16111615","journal-title":"Pharmaceuticals (Basel Switzerland)"},{"key":"9870_CR120","unstructured":"U.S. Food and Drug Administration (2024) Center for Biologics Evaluation and Research (CBER). https:\/\/www.fda.gov\/about-fda\/fda-organization\/center-biologics-evaluation-and-research-cber"},{"issue":"8","key":"9870_CR121","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/antibiotics10080999","volume":"10","author":"AH Azam","year":"2021","unstructured":"Azam AH, Tan XE, Veeranarayanan S, Kiga K, Cui L (2021) Bacteriophage Technology and Modern Medicine. Antibiot (Basel Switzerland) 10(8):999. https:\/\/doi.org\/10.3390\/antibiotics10080999","journal-title":"Antibiot (Basel Switzerland)"},{"key":"9870_CR122","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3389\/fmicb.2019.02289","volume":"10","author":"M Mutti","year":"2019","unstructured":"Mutti M, Corsini L (2019) Robust approaches for the production of active ingredient and drug product for human phage therapy. Front Microbiol 10:2289. https:\/\/doi.org\/10.3389\/fmicb.2019.02289","journal-title":"Front Microbiol"},{"key":"9870_CR123","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fmicb.2020.01161","volume":"11","author":"L Bretaudeau","year":"2020","unstructured":"Bretaudeau L, Tremblais K, Aubrit F, Meichenin M, Arnaud I (2020) Good Manufacturing Practice (GMP) compliance for phage therapy Medicinal products. Front Microbiol 11:1161. https:\/\/doi.org\/10.3389\/fmicb.2020.01161","journal-title":"Front Microbiol"},{"issue":"1","key":"9870_CR124","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/phe\/phaa003","volume":"13","author":"J Anomaly","year":"2020","unstructured":"Anomaly J (2020) The future of phage: ethical challenges of using phage therapy to treat bacterial infections. Public Health Ethics 13(1):82\u201388. https:\/\/doi.org\/10.1093\/phe\/phaa003","journal-title":"Public Health Ethics"},{"issue":"4","key":"9870_CR125","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/microorganisms10040717","volume":"10","author":"R V\u00e1zquez","year":"2022","unstructured":"V\u00e1zquez R, D\u00edez-Mart\u00ednez R, Domingo-Calap P, Garc\u00eda P, Guti\u00e9rrez D, Muniesa M, Ruiz-Ruig\u00f3mez M, Sanju\u00e1n R, Tom\u00e1s M, Tormo-Mas M\u00c1, Garc\u00eda P (2022) Essential Topics for the Regulatory Consideration of Phages as clinically Valuable Therapeutic agents: a perspective from Spain. Microorganisms 10(4):717. https:\/\/doi.org\/10.3390\/microorganisms10040717","journal-title":"Microorganisms"},{"key":"9870_CR126","doi-asserted-by":"publisher","first-page":"907314","DOI":"10.3389\/fcimb.2022.907314","volume":"12","author":"L Plumet","year":"2022","unstructured":"Plumet L, Ahmad-Mansour N, Dunyach-Remy C, Kissa K, Sotto A, Lavigne JP, Costechareyre D, Molle V (2022) Bacteriophage therapy for Staphylococcus Aureus infections: a review of animal models, treatments, and clinical trials. Front Cell Infect Microbiol 12:907314. https:\/\/doi.org\/10.3389\/fcimb.2022.907314","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"9870_CR127","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1128\/AAC.50.4.1268-1275.2006","volume":"50","author":"JJ Curtin","year":"2006","unstructured":"Curtin JJ, Donlan RM (2006) Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50(4):1268\u20131275. https:\/\/doi.org\/10.1128\/AAC.50.4.1268-1275.2006PMID: 16569839; PMCID: PMC1426991","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"9870_CR128","doi-asserted-by":"publisher","first-page":"e47742","DOI":"10.1371\/journal.pone.0047742","volume":"7","author":"K Fukuda","year":"2012","unstructured":"Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, Fukushima A (2012) Pseudomonas aeruginosa Keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS ONE 7(10):e47742. https:\/\/doi.org\/10.1371\/journal.pone.0047742","journal-title":"PLoS ONE"},{"issue":"1","key":"9870_CR129","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1128\/IAI.70.1.204-210.2002","volume":"70","author":"B Biswas","year":"2002","unstructured":"Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of Vancomycin-resistant Enterococcus faecium. Infect Immun 70(1):204\u2013210. https:\/\/doi.org\/10.1128\/IAI.70.1.204-210.2002","journal-title":"Infect Immun"},{"issue":"7","key":"9870_CR130","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-4362.2002.01451.x","volume":"41","author":"K Markoishvili","year":"2002","unstructured":"Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A (2002) A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol 41(7):453\u2013458. https:\/\/doi.org\/10.1046\/j.1365-4362.2002.01451.x","journal-title":"Int J Dermatol"},{"key":"9870_CR131","doi-asserted-by":"publisher","DOI":"10.1177\/1534734619881076","author":"DR Patel","year":"2019","unstructured":"Patel DR, Bhartiya SK, Kumar R, Shukla VK, Nath G (2019) Use of customized bacteriophages in the treatment of chronic nonhealing wounds: a prospective study. Int J Low Extrem Wounds. https:\/\/doi.org\/10.1177\/1534734619881076","journal-title":"Int J Low Extrem Wounds"},{"key":"9870_CR132","doi-asserted-by":"publisher","unstructured":"Schuch R, Nelson D, Fischetti VA (2002) A bacteriolytic agaent that detects and kills Bacillus anthracis. Nature. ;418(6900):884-9. https:\/\/doi.org\/10.1038\/nature01026. PMID: 12192412","DOI":"10.1038\/nature01026"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09870-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09870-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09870-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:08:19Z","timestamp":1738728499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09870-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9870"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09870-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate were not applicable to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"925"}}